

Article type

Commentary

Paper title

Diversity in immunogenomics: the value and the challenge

Authors and affiliations

Kerui Peng

Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, CA, USA

keruipen@usc.edu

Yana Safonova

Computer Science and Engineering Department, University of California San Diego, San Diego, USA, CA; Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA

isafonova@eng.ucsd.edu

Mikhail Shugay

Skolkovo Institute of Science and Technology, Moscow, Russia / Bolshoy Bulvar, 30, Moscow, Moscow Oblast

mikhail.shugay@gmail.com

Alice Popejoy

Department of Biomedical Data Science (DBDS), Stanford University, Stanford, CA, USA

apopejoy@stanford.edu

Felix Breden

Department of biological sciences, Simon Fraser University, Burnaby bc v5a 1s6 Canada

breden@sfu.ca

Petter Brodin

Science for Life Laboratory, Dept. of Women's and Children Health, Karolinska Institutet, Sweden

Pediatric Rheumatology, Karolinska University Hospital, Sweden

petter.brodin@ki.se

Amanda M. Burkhardt

Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, CA,
USA

aburkhar@usc.edu

Carlos Bustamante

Department of Biomedical Data Science (DBDS), Stanford University, Stanford, CA, USA

cdbustam@stanford.edu

Van-Mai Cao-Lormeau

Laboratory of research on Infectious Vector-borne diseases, Institut Louis Malardé, French
Polynesia

mlormeau@ilm.pf

Martin M. Corcoran

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden

martin.corcoran@ki.se

Darragh Duffy

Translational Immunology Lab, Institut Pasteur, 25 Rue du Dr Roux, Paris, France

darragh.duffy@pasteur.fr

Macarena Fuentes Guajardo

Health Sciences Faculty, University of Tarapacá, Arica, Chile

macarena.fuentes.14@alumni.ucl.ac.uk

Ricardo Fujita

Centro de Genética y Biología Molecular, Universidad de San Martín de Porres, Alameda del
Corregidor 1531, La Molina, Lima 12, Perú

rfujitaa@usmp.pe

Victor Greiff

Department of Immunology, University of Oslo, Norway

victor.greiff@medisin.uio.no

Vanessa D. Jönsson

Departments of Computational and Quantitative Medicine and Hematology, Beckman Research
Institute, City of Hope, Duarte, CA, USA

vjonsson@coh.org

Xiao Liu

Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen, China
airson_liu@163.com

Lluis Quintana-Murci

Human Evolutionary Genetics Unit, CNRS UMR200, 25-28 rue du Dr Roux, Paris, France
Human Genomics and Evolution, Collège de France, 11 Place Marcelin Berthelot, Paris, France
lluis.quintana-murci@pasteur.fr

Maura Rossetti

UCLA Immunogenetics Center, Department of Pathology and Laboratory Medicine, David
Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
maurarossetti@gmail.com

Jianming Xie

Department of Pharmacology & Pharmaceutical Sciences, School of Pharmacy, University of
Southern California, CA, USA
jianminx@usc.edu

Gur Yaari

Faculty of Engineering, Bar Ilan Institute of Nanotechnologies and Advanced Materials, Bar Ilan
University, Ramat Gan, Israel
gur.yaari@biu.ac.il

Wei Zhang

Department of Computer Science, City University of Hong Kong, Hong Kong, China
wzhang287-c@my.cityu.edu.hk

William D. Lees

Institute of Structural and Molecular Biology, Birkbeck College, London, UK
william@lees.org.uk

Purvesh Khatri

Institute for Immunity, Transplantation and Infection, School of Medicine, Stanford University,
CA, USA
Center for Biomedical Research, Department of Medicine, School of Medicine, Stanford
University, CA, USA
pkhatri@stanford.edu

Houda Alachkar†

Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, CA,
USA

alachkar@usc.edu

Cathrine Scheepers†

Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health
Laboratory Service and the Antibody Immunity Research Unit, School of Pathology, University
of the Witwatersrand, Johannesburg, South Africa

cathrinem@nicd.ac.za

Corey T. Watson†

Department of Biochemistry and Molecular Genetics, University of Louisville School of
Medicine, Louisville, KY, USA

corey.watson@louisville.edu

Gunilla B. Karlsson Hedestam†

Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 171 77 Stockholm,
Sweden

gunilla.karlsson.hedestam@ki.se

Serghei Mangul†

Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, CA,
USA

serghei.mangul@gmail.com

*Correspondence: serghei.mangul@gmail.com (S. Mangul)

†These authors contributed equally to the work.

Abstract

With the recent advent of high-throughput sequencing technologies, and the associated new discoveries and developments, the fields of immunogenomics and adaptive immune receptor repertoire research are facing both opportunities and challenges. The majority of immunogenomics studies have been primarily conducted in cohorts of European ancestry, restricting the ability to detect and analyze variation in human adaptive immune responses across populations and limiting their applications. By leveraging biological and clinical heterogeneity across different populations in omics data and expanding the populations that are included in immunogenomics research, we can enhance our understanding of human adaptive immune responses, promote the development of effective diagnostics and treatments, and eventually advance precision medicine.

Main

Lessons about the importance of diversity from genomics studies

Genomics researchers have mainly focused on individuals of European ancestry, at the expense of learning from the largest and most genetically diverse populations. For example, 78% of individuals included in genome-wide association studies (GWAS) reported in the GWAS Catalog (<https://www.ebi.ac.uk/gwas/home>) through January 2019 are of European descent¹, while Asian populations account for 59.5% of the world population based on the Population Reference Bureau's World Population Data Sheet (<https://www.prb.org/datasheets/>). Though partially due to inadequate sampling of non-European populations, even when diverse datasets are available, researchers tend to exclude data from minority groups when conducting statistical

analyses². This limits the discovery of genetic diversity contributing to Mendelian diseases and to explore associations between genetic variants and trait variation across populations.

In recent years, awareness has been increasing about the limited generalizability of findings across populations, motivating the inclusion of diverse, multiethnic populations in large-scale genomic studies^{3,4}. For example, novel single nucleotide polymorphisms (SNPs) that are clinically associated with warfarin dosing were discovered in large scale genomics studies in individuals of African descent that had not been discovered in Europeans^{5,6}. Whole-genome sequencing in individuals of African descent⁷⁻⁹ and whole-exome sequencing in a southern African population¹⁰ have also improved understanding of genetic variation in underrepresented populations. More recently, meta-analysis of GWAS on a wide range of populations promoted the discovery of new gene- and variant-trait associations. Bentley and colleagues conducted a meta-analysis including 133,805 individuals of European, African, Asian, and Hispanic origins, discovering 13 novel loci associated with gene-smoking interaction and serum lipids¹¹. A recent GWAS in 746,667 individuals revealed 5,552 trait-variant associations, with 99 newly discovered associations among non-European populations¹².

Additional efforts have been made through international collaborations to establish reference genome datasets and recommendations for research in diverse populations; including the GenomeAsia 100K Project, the Human Heredity and Health in Africa (H3Africa) initiative, and the Clinical Genome Resource (ClinGen) Ancestry and Diversity Working Group (ADWG)¹³⁻¹⁶. Khatri and colleagues discovered the 3-gene signature for diagnosis of tuberculosis based on transcriptome profiles of participants from 11 countries¹⁷, a finding that was generalized to

patient populations from every inhabited continent in a span of 3 years^{18,19}. Most importantly, the 3-gene signature has been clinically translated to the point-of-care test by Cepheid²⁰.

The inclusion of diverse populations in genomic studies has demonstrated benefits in the discovery and interpretation of gene-trait associations. Similarly, greater diversity in immunogenomics research will enable the discovery of novel genetic traits associated with immune system phenotypes that are common across populations. Broader inclusion of diverse populations may also enable researchers to address genetic heterogeneity in the context of translational research and clinical drug development, possibly revealing clinically relevant genomic signatures that are more prevalent in some populations than others.

The evolution of immunogenomics

Immunogenomics is a field in which genetic information at different levels of biological organization (epigenetics, transcriptomics, metabolomics, cells, tissues, and clinical data) has been characterized and utilized to understand the immune system and immune responses. Here we focus on the analysis of the adaptive immune repertoire; other modalities are covered elsewhere²¹. T cell receptors (TCRs), B cell receptors (BCRs), human leukocyte antigen (HLA), and killer cell immunoglobulin-like receptors (KIRs) play central roles in the immune system. Thus analyses of these loci are important components of immunogenomics studies. T cells and B cells respond to antigens through their diverse repertoires of TCRs and BCRs, which are formed through the process of V(D)J recombination. Capturing the characteristics of entire TCR and BCR repertoires was not possible until the development of high-throughput sequencing techniques in the late 2000s. Freeman and colleagues introduced 5' rapid amplification of cDNA end (5'RACE) PCR to amplify TCR cDNA and to characterize TCR repertoires²². Additionally,

Weinstein and colleagues sequenced the first antibody repertoire in zebrafish in 2009²³, creating the foundation of adaptive immune receptor repertoire sequencing (AIRR-seq) technologies. In 2010, the initial application of AIRR-seq technology in humans was made by Boyd and colleagues²⁴. Since then, studies including AIRR-seq have seen exponential growth, and findings from these studies have shaped our current understanding of the immune repertoire and its influence on human health^{25–28}.

AIRR-seq analysis and other immunogenomics studies have offered new opportunities for deepening our understanding of the immune system in the context of a variety of human diseases, such as infectious diseases^{29–33}, cancer^{34,35}, autoimmune conditions^{36–38}, and neurodegenerative disease³⁹. Furthermore, AIRR-seq data provides information on expression profiles, germline V, D, and J gene usage, complementarity determining region (CDR) diversity, and somatic hypermutation (SHM). Computational methods have been developed to infer germline TCRs and BCRs genes from AIRR-seq data for analysis^{40–44}(Supplemental Table 1). RNA-seq has traditionally been mapped to study entire cellular populations instead of amplifying at the specific regions. Given the complexity of the TCR and BCR genomic loci, the accurate determination of germline immune receptor genes, from bulk RNA-seq or whole-genome sequencing, has proved challenging⁴⁵. Several computational methods show promise^{46–48}, but the mapping rate and accuracy remain to be improved. Additionally, a wide-scale comparison is needed between results obtained from methods for deriving germline receptor genes from RNA-seq studies, those obtained from established methods such as, targeted PCR and sequencing of genomic DNA, the sequencing and assembly of bacterial artificial chromosome (BAC) and

fosmid clones⁴⁹, and those from more recent methods such as inference from AIRR-seq repertoires⁵⁰.

The missing diversity in immunogenomics studies

Many population genetic differences have been observed in genomics studies and immunogenomics is no exception^{51–53}. For example, novel variants in germline immunoglobulin genes have been discovered in underrepresented populations not found in studies with only individuals of European descent^{49,54–56}. Despite these efforts to uncover immunogenetic diversity across populations, the majority of AIRR-seq studies and immunogenomics research have been conducted in individuals of European descent, leaving others underrepresented^{57,58}. Furthermore, to date, no systematic analysis has been conducted to quantify the extent of diversity in immunogenomics studies. This has limited our ability to validate findings from European populations and determine their generalizability, in addition to limiting opportunities for the discovery of novel variants in non-European populations⁵⁹. For example, HLA risk haplotypes (HLA DQ2 and DQ8) for autoimmune diseases are relatively high in the European population which may contribute to the prevalence of the autoimmune diseases⁶⁰. KIR A2 and B haplotypes are associated with type 1 diabetes in European descent⁶¹. However, it is unclear whether these immunogenomics features are relevant in other populations due to the studies' lack of diversity. Missing information hinders the advancement of precision medicine as it leaves uncertainty with respect to the genetic basis of treatment outcomes and health disparities⁵⁸. Moreover, it limits our understanding of how pathogens have exerted selective pressures on immune-related genes in populations living in different environments, and thus on infectious disease manifestation⁶².

The current public databases of adaptive immune receptor germline genes are essential for AIRR-seq analysis and immunogenomics studies. However, the most widely used reference database for immunogenetics data, the international ImMunoGeneTics information system (IMGT)⁶³, lacks a comprehensive set of human TCR and BCR alleles representing diverse populations worldwide. The same issue exists in HLA databases: over 70% of rare HLA variants from Oceania and west Asia populations were found to be absent in the 1000 Genomes Project panel⁶⁴. There is still more uncertainty due to the fact that descriptions of sample populations in databases are often self-identified based on geography or ethnicity, rather than genetic ancestry. However, progress has been made to address this issue in immunogenomics studies. For example, the AIRR Community, an international community formed to promote high standard research in adaptive immune repertoire research, introduced the Open Germline Receptor Database (OGRDB) in September 2019 as a resource platform for germline gene discovery and validation from AIRR-seq data, to enrich the IMGT database⁶⁵. Collaborators in our team also created VDJbase, a platform for the inferred genotypes and haplotypes from AIRR-seq data⁶⁶. These efforts provide the opportunities to infer genetic ancestry. Nevertheless, the majority of available germline sequences either lack population-level annotations or are biased toward samples of European descent. We argue that this shortcoming must be addressed through focused efforts that seek to include more diverse populations in immunogenomics research.

Key steps for the inclusion of population diversity in immunogenomics research

As an interdisciplinary group, with expertise in biomedical and translational research, population biology, computational biology, and immunogenomics, we wish to raise awareness about the value of including diverse populations in AIRR-seq and immunogenetics research. In the areas of

genetic disease research and cancer genomics, enhanced genetic diversity has led to demonstrable insights^{67,68}. However, the field of immunogenomics has yet to benefit from a similar growth in diversity. At the current stage of the global COVID-19 pandemic, numerous vaccine trials are underway in many countries worldwide, offering opportunities to investigate genetic factors in vaccine responses. Yet, this will require careful clinical study designs that can effectively address confounding factors such as environmental and socio-economic differences. These factors play an important role in COVID-19 outcomes but are often overlooked in favor of searching for the genetic underpinnings of clinical outcomes. Incomplete representation of diverse populations limits our capacity to understand even the genetic architecture behind assessed immunological and clinical phenotypes, and ideally this should be investigated alongside environmental risk factors for disease. Previous studies have shown associations between genetic variants and clinical presentation of disease^{69,70} and specific IG germline alleles have been found to be presented preferentially in response to pathogens such as influenza²⁹, HIV-1⁷¹, Zika⁷², and SARS CoV-2⁷³. We expect that vaccine and infection outcomes can also be shaped by genetic variability, including specific effects driven by immune-related genes⁵⁸. Here, we make several recommendations for increasing diversity in immunogenomics research.

First, we propose that the community should make a greater effort to include underrepresented populations in AIRR-seq and immunogenomics studies. Already, those that have conducted AIRR-seq in populations of non-European descent have uncovered evidence for extensive germline diversity. For example, in a study of South African HIV patients, Scheepers and colleagues discovered 123 *IGHV* alleles that were not represented in IMGT⁵⁴. This promoted the HIV vaccine design by understanding the immunoglobulin heavy chain variable region (IGHV)

profile in the South African population. In a study in the Papua New Guinea population, one novel *IGHV* gene and 16 *IGHV* allelic variants were identified from AIRR-seq data⁵⁵. These discoveries of novel alleles indicate the need to generate population-based AIRR-seq datasets. We do not recommend generalizing AIRR-seq findings to populations that are underrepresented in research, due to missing variation and lack of validation, which limits our ability to leverage AIRR-seq datasets in biomedical applications. Therefore, increasing population diversity in immunogenomics studies can lead to improvements in a wide range of applications, including drug discovery and development, vaccine design and development. Promoting precision medicine for underrepresented populations and improving predictions for treatment outcomes will become more feasible in the future with broader participation and inclusion.

Second, we argue that there are existing genomic datasets that could potentially be leveraged to augment IG/TCR germline databases, and inform the interpretation of AIRR-seq and immunogenomics studies across populations. Extraction of population immunogenomics information from existing genomic datasets could be an effective strategy, as well as carefully embracing non-targeted sequencing data (eg. RNA-seq) to focus on genetic diversity of samples. Ancestry-associated genetic markers in short-read genome sequencing may help overcome the difficulties of relying on sample metadata in AIRR-seq datasets. This may also be time-efficient relative to waiting for the availability of sufficiently diverse AIRR-seq datasets. Researchers have attempted to utilize paired-end RNA-seq data in the Cancer Genome Atlas (TCGA) to infer the complementarity determining region 3 (CDR3) of tumor-infiltrating T-cells⁷⁴, and to apply a computational method to RNA-seq data in the Genotype-Tissue Expression Consortium (GTEx) to profile immunoglobulin repertoires⁴⁸. Similar ideas could be adapted to the direct prediction of

allelic variants from short-read genomic sequence data^{75,76}. However, challenges need to be overcome, including the high levels of copy number variation and segmental duplication in the BCR and TCR loci, and the need for protocols to validate novel allelic variants gleaned from short-read sequencing data^{45,77}. New methodologies and computational approaches may facilitate the inclusion of diverse population datasets into existing databases that should eventually reflect the genomic immunological diversity present in populations around the globe. Such a database would provide researchers with resources to tackle key questions in biomedical research and human evolution, including the reconstruction of past migratory routes, genetic adaptation of human populations to infectious diseases⁷⁸, cultural demography of the human immunome, the influence of environmental factors in human immune repertoires, changes in HLA-driven autoimmunity across ancestral populations and how this has changed with increased mixing of populations and genes, and the effects of pathogen-driven selective pressures on immune-related genes and on infectious disease manifestation⁶².

Finally, we suggest the need for additional infrastructure and expertise in regions and countries with populations underrepresented in research, and to enhance collaborations between countries, which are critical in minimizing global health disparities. Online training sessions that are customized for conducting immunogenomics research in diverse populations would be beneficial to the biomedical community, perhaps especially in those regions. The content of these trainings might include participant recruitment strategies with a commitment to outreach and education to increase participation, sample collection methods, steps to running sequence experiments onsite or in collaboration with other academic institutions or commercial companies, uploading sequencing data to appropriate repositories, and performing bioinformatics analyses. Virtual

learning platforms for bioinformaticians have been established by members in our group, and these could be leveraged to provide such trainings⁷⁹. Our interdisciplinary group consists of leading researchers from 13 countries, including the US, Canada, Norway, France, Sweden, Russia, the UK, Israel, China, South Africa, Chile, Peru, and French Polynesia. We share concerns about the lack of diversity in immunogenomics and embrace the need for engaging our combined efforts to tackle this challenge. To spearhead the enterprise of fostering diversity in the field, we have formed this task force with the aim of developing a global consortium on diversity in immunogenomics. This consortium will seek to promote inclusive, international, and interdisciplinary research, supported by transparent and open-source learning materials and datasets, with the goal of enhancing representation of diverse populations in immunogenomics.

Acknowledgments

Cathrine Scheepers' work has been supported by National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U01AI136677.

We thank Dr. Nicky Mulder for the valuable comments that greatly improved the manuscript.

References

1. Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic Studies. *Cell* **177**, 1080 (2019).
2. Ben-Eghan, C. *et al.* Don't ignore genetic data from minority populations. *Nature* vol. 585 184–186 (2020).
3. McGuire, A. L. *et al.* The road ahead in genetics and genomics. *Nat. Rev. Genet.* (2020) doi:10.1038/s41576-020-0272-6.
4. Mills, M. C. & Rahal, C. A scientometric review of genome-wide association studies. *Commun Biol*

- 2, 9 (2019).
5. Perera, M. A. *et al.* Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. *Lancet* **382**, 790–796 (2013).
 6. Mitchell, C., Gregersen, N. & Krause, A. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. *Pharmacogenomics* **12**, 953–963 (2011).
 7. Sherman, R. M. *et al.* Assembly of a pan-genome from deep sequencing of 910 humans of African descent. *Nat. Genet.* **51**, 30–35 (2019).
 8. Gurdasani, D. *et al.* The African Genome Variation Project shapes medical genetics in Africa. *Nature* **517**, 327–332 (2015).
 9. Choudhury, A. *et al.* Whole-genome sequencing for an enhanced understanding of genetic variation among South Africans. *Nat. Commun.* **8**, 2062 (2017).
 10. Retshabile, G. *et al.* Whole-Exome Sequencing Reveals Uncaptured Variation and Distinct Ancestry in the Southern African Population of Botswana. *Am. J. Hum. Genet.* **102**, 731–743 (2018).
 11. Bentley, A. R. *et al.* Multi-ancestry genome-wide gene-smoking interaction study of 387,272 individuals identifies new loci associated with serum lipids. *Nat. Genet.* **51**, 636–648 (2019).
 12. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. *Cell* **182**, 1198–1213.e14 (2020).
 13. H3Africa Consortium *et al.* Research capacity. Enabling the genomic revolution in Africa. *Science* **344**, 1346–1348 (2014).
 14. GenomeAsia100K Consortium. The GenomeAsia 100K Project enables genetic discoveries across Asia. *Nature* **576**, 106–111 (2019).
 15. Mulder, N. *et al.* H3Africa: current perspectives. *Pharmacogenomics. Pers. Med.* **11**, 59–66 (2018).
 16. Popejoy, A. B. *et al.* The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics. *Hum. Mutat.* **39**, 1713–1720 (2018).
 17. Sweeney, T. E., Braviak, L., Tato, C. M. & Khatri, P. Genome-wide expression for diagnosis of

- pulmonary tuberculosis: a multicohort analysis. *Lancet Respir Med* **4**, 213–224 (2016).
18. Warsinske, H. C. *et al.* Assessment of Validity of a Blood-Based 3-Gene Signature Score for Progression and Diagnosis of Tuberculosis, Disease Severity, and Treatment Response. *JAMA Netw Open* **1**, e183779 (2018).
 19. Gupta, R. K. *et al.* Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. *Lancet Respir Med* **8**, 395–406 (2020).
 20. Sodersten, E. *et al.* Diagnostic accuracy study of a novel blood-based assay for identification of TB in people living with HIV. doi:10.1101/2020.06.10.20127209.
 21. Pulendran, B. & Davis, M. M. The science and medicine of human immunology. *Science* **369**, (2020).
 22. Freeman, J. D., Warren, R. L., Webb, J. R., Nelson, B. H. & Holt, R. A. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. *Genome Res.* **19**, 1817–1824 (2009).
 23. Weinstein, J. A., Jiang, N., White, R. A., 3rd, Fisher, D. S. & Quake, S. R. High-throughput sequencing of the zebrafish antibody repertoire. *Science* **324**, 807–810 (2009).
 24. Boyd, S. D. *et al.* Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. *J. Immunol.* **184**, 6986–6992 (2010).
 25. Tumeh, P. C. *et al.* PD-1 blockade induces responses by inhibiting adaptive immune resistance. *Nature* **515**, 568–571 (2014).
 26. Han, A., Glanville, J., Hansmann, L. & Davis, M. M. Linking T-cell receptor sequence to functional phenotype at the single-cell level. *Nat. Biotechnol.* **32**, 684–692 (2014).
 27. Briney, B., Inderbitzin, A., Joyce, C. & Burton, D. R. Commonality despite exceptional diversity in the baseline human antibody repertoire. *Nature* **566**, 393–397 (2019).
 28. Brown, A. J. *et al.* Augmenting adaptive immunity: progress and challenges in the quantitative engineering and analysis of adaptive immune receptor repertoires. *Molecular Systems Design & Engineering* vol. 4 701–736 (2019).
 29. Avnir, Y. *et al.* IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates

- with IGHV utilization shifts and varies by ethnicity. *Sci. Rep.* **6**, 20842 (2016).
30. Setliff, I. *et al.* Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. *Cell Host Microbe* **23**, 845–854.e6 (2018).
 31. Roskin, K. M. *et al.* Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. *Nat. Immunol.* **21**, 199–209 (2020).
 32. Kreer, C., Gruell, H., Mora, T., Walczak, A. M. & Klein, F. Exploiting B Cell Receptor Analyses to Inform on HIV-1 Vaccination Strategies. *Vaccines (Basel)* **8**, (2020).
 33. Emerson, R. O. *et al.* Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire. *Nature Genetics* vol. 49 659–665 (2017).
 34. Liu, X. S. & Mardis, E. R. Applications of Immunogenomics to Cancer. *Cell* **168**, 600–612 (2017).
 35. Sharonov, G. V., Serebrovskaya, E. O., Yuzhakova, D. V., Britanova, O. V. & Chudakov, D. M. B cells, plasma cells and antibody repertoires in the tumour microenvironment. *Nat. Rev. Immunol.* **20**, 294–307 (2020).
 36. Simnica, D. *et al.* High-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias. *Front. Immunol.* **10**, 1897 (2019).
 37. Bashford-Rogers, R. J. M. *et al.* Analysis of the B cell receptor repertoire in six immune-mediated diseases. *Nature* vol. 574 122–126 (2019).
 38. Liu, X. *et al.* T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis. *Ann. Rheum. Dis.* **78**, 1070–1078 (2019).
 39. Gate, D. *et al.* Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. *Nature* vol. 577 399–404 (2020).
 40. Gadala-Maria, D. *et al.* Identification of Subject-Specific Immunoglobulin Alleles From Expressed Repertoire Sequencing Data. *Front. Immunol.* **10**, 129 (2019).
 41. Corcoran, M. M. *et al.* Production of individualized V gene databases reveals high levels of immunoglobulin genetic diversity. *Nat. Commun.* **7**, 13642 (2016).
 42. Zhang, W. *et al.* IMPre: An Accurate and Efficient Software for Prediction of T- and B-Cell

- Receptor Germline Genes and Alleles from Rearranged Repertoire Data. *Frontiers in Immunology* vol. 7 (2016).
43. Safonova, Y. & Pevzner, P. A. De novo Inference of Diversity Genes and Analysis of Non-canonical V(DD)J Recombination in Immunoglobulins. *Frontiers in Immunology* vol. 10 (2019).
 44. Bhardwaj, V., Franceschetti, M., Rao, R., Pevzner, P. A. & Safonova, Y. Automated analysis of immunosequencing datasets reveals novel immunoglobulin D genes across diverse species. *PLoS Comput. Biol.* **16**, e1007837 (2020).
 45. Rodriguez, O. L. *et al.* A Novel Framework for Characterizing Genomic Haplotype Diversity in the Human Immunoglobulin Heavy Chain Locus. *Frontiers in Immunology* **11**, 2136 (2020).
 46. Li, B. *et al.* Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA-seq data. *Nature Genetics* vol. 49 482–483 (2017).
 47. Mose, L. E. *et al.* Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V'DJer. *Bioinformatics* vol. 32 3729–3734 (2016).
 48. Mandric, I. *et al.* Profiling immunoglobulin repertoires across multiple human tissues using RNA sequencing. *Nat. Commun.* **11**, 3126 (2020).
 49. Watson, C. T. *et al.* Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation. *Am. J. Hum. Genet.* **92**, 530–546 (2013).
 50. Ohlin, M. *et al.* Inferred Allelic Variants of Immunoglobulin Receptor Genes: A System for Their Evaluation, Documentation, and Naming. *Front. Immunol.* **10**, 435 (2019).
 51. Brzezinski, J. L., Deka, R., Menon, A. G., Glass, D. N. & Choi, E. Variability in TRBV haplotype frequency and composition in Caucasian, African American, Western African and Chinese populations. *Int. J. Immunogenet.* **32**, 413–420 (2005).
 52. Mackelprang, R. *et al.* Sequence diversity, natural selection and linkage disequilibrium in the human T cell receptor alpha/delta locus. *Human Genetics* vol. 119 255–266 (2006).
 53. Mackelprang, R. *et al.* Sequence variation in the human T-cell receptor loci. *Immunological Reviews*

- vol. 190 26–39 (2002).
54. Scheepers, C. *et al.* Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire. *The Journal of Immunology* vol. 194 4371–4378 (2015).
 55. Wang, Y. *et al.* Genomic screening by 454 pyrosequencing identifies a new human IGHV gene and sixteen other new IGHV allelic variants. *Immunogenetics* **63**, 259–265 (2011).
 56. Romo-González, T., Morales-Montor, J., Rodríguez-Dorantes, M. & Vargas-Madrado, E. Novel substitution polymorphisms of human immunoglobulin VH genes in Mexicans. *Hum. Immunol.* **66**, 732–740 (2005).
 57. Watson, C. T. & Breden, F. The immunoglobulin heavy chain locus: genetic variation, missing data, and implications for human disease. *Genes Immun.* **13**, 363–373 (2012).
 58. Watson, C. T., Glanville, J. & Marasco, W. A. The Individual and Population Genetics of Antibody Immunity. *Trends Immunol.* **38**, 459–470 (2017).
 59. Pogorelyy, M. V. *et al.* Exploring the pre-immune landscape of antigen-specific T cells. *Genome Med.* **10**, 68 (2018).
 60. Kårhus, L. L., Thuesen, B. H., Skaaby, T., Rumessen, J. J. & Linneberg, A. The distribution of HLA DQ2 and DQ8 haplotypes and their association with health indicators in a general Danish population. *United European Gastroenterology Journal* vol. 6 866–878 (2018).
 61. Traherne, J. A. *et al.* KIR haplotypes are associated with late-onset type 1 diabetes in European–American families. *Genes & Immunity* vol. 17 8–12 (2016).
 62. Quintana-Murci, L. Human Immunology through the Lens of Evolutionary Genetics. *Cell* **177**, 184–199 (2019).
 63. Lefranc, M.-P. *et al.* IMGT®, the international ImMunoGeneTics information system® 25 years on. *Nucleic Acids Res.* **43**, D413–22 (2015).
 64. Abi-Rached, L. *et al.* Immune diversity sheds light on missing variation in worldwide genetic diversity panels. *PLoS One* **13**, e0206512 (2018).
 65. Lees, W. *et al.* OGRDB: a reference database of inferred immune receptor genes. *Nucleic Acids Res.*

- 48, D964–D970 (2020).
66. Omer, A. *et al.* VDJbase: an adaptive immune receptor genotype and haplotype database. *Nucleic Acids Res.* **48**, D1051–D1056 (2020).
 67. Kruszka, P. *et al.* Williams-Beuren syndrome in diverse populations. *Am. J. Med. Genet. A* **176**, 1128–1136 (2018).
 68. Jaratlerdsiri, W. *et al.* Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer. *Cancer Res.* **78**, 6736–6746 (2018).
 69. Initiative, T. C.-19 H. G. & The COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *European Journal of Human Genetics* vol. 28 715–718 (2020).
 70. Ellinghaus, D. *et al.* Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N. Engl. J. Med.* (2020) doi:10.1056/NEJMoa2020283.
 71. Huang, J. *et al.* Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. *Immunity* **45**, 1108–1121 (2016).
 72. Robbiani, D. F. *et al.* Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. *Cell* **169**, 597–609.e11 (2017).
 73. Yuan, M. *et al.* Structural basis of a shared antibody response to SARS-CoV-2. *Science* **369**, 1119–1123 (2020).
 74. Li, B. *et al.* Landscape of tumor-infiltrating T cell repertoire of human cancers. *Nat. Genet.* **48**, 725–732 (2016).
 75. Luo, S., Yu, J. A., Li, H. & Song, Y. S. Worldwide genetic variation of the IGHV and TRBV immune receptor gene families in humans. *Life Sci Alliance* **2**, (2019).
 76. Yu, Y., Ceredig, R. & Seoighe, C. Correction: A Database of Human Immune Receptor Alleles Recovered from Population Sequencing Data. *J. Immunol.* **198**, 3758 (2017).
 77. Watson, C. T. *et al.* Comment on ‘A Database of Human Immune Receptor Alleles Recovered from

Population Sequencing Data'. *The Journal of Immunology* vol. 198 3371–3373 (2017).

78. Quach, H. & Quintana-Murci, L. Living in an adaptive world: Genomic dissection of the genus *Homo* and its immune response. *Journal of Experimental Medicine* vol. 214 877–894 (2017).
79. Mangul, S. *et al.* How bioinformatics and open data can boost basic science in countries and universities with limited resources. *Nat. Biotechnol.* **37**, 324–326 (2019).

Supplementary table

Supplemental table 1. Tools for inference of germline TR/IG genes from AIRR-Seq data

Tool	Type of receptors	Type of inferring genes	Needs gene database for inference	Comment
TIgGER ⁴⁰	BCR	V	yes	TIgGER assigns AIRR-Seq reads to V genes from the database and reports a list of V gene alleles (both known alleles and alleles with modifications).
IgDiscover ⁴¹	BCR	V, J	yes	IgDiscover uses the database for annotation of AIRR-Seq reads, clusters reads with similar annotations, and reports both known and novel V genes.
IMPre ⁴²	BCR / TCR	V, J	no	IMPre infers V and J genes from clusters of similar AIRR-Seq reads and uses a germline database (if available) for annotation of the inferred genes.
IgScout ⁴³	BCR	D, J	no	Both IgScout and MINING-D infer D genes as abundant substrings of CDR3s of AIRR-Seq reads and use a germline database (if available) for annotation of the inferred genes.
MINING-D ⁴⁴	BCR / TCR	D	no	